Your browser doesn't support javascript.
loading
Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals.
Khan, Arifa S; Blümel, Johannes; Deforce, Dieter; Gruber, Marion F; Jungbäck, Carmen; Knezevic, Ivana; Mallet, Laurent; Mackay, David; Matthijnssens, Jelle; O'Leary, Maureen; Theuns, Sebastiaan; Victoria, Joseph; Neels, Pieter.
Affiliation
  • Khan AS; Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Electronic address: arifa.khan@fda.hhs.gov.
  • Blümel J; Paul-Ehrlich-Institut, Langen, Germany.
  • Deforce D; Ghent University, Ghent, Belgium.
  • Gruber MF; Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Jungbäck C; International Association for Biological Standardization for Europe, Lyon, France.
  • Knezevic I; World Health Organization, Geneva, Switzerland.
  • Mallet L; Sanofi Pasteur, Lyon, France.
  • Mackay D; Advisor Veterinary Vaccinology, London, UK.
  • Matthijnssens J; University of Leuven, Rega Institute for Medical Research, Leuven, Belgium.
  • O'Leary M; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium.
  • Theuns S; Ghent University, Ghent, Belgium.
  • Victoria J; Boehringer Ingelheim, Ingelheim am Rhein, Germany.
  • Neels P; International Association for Biological Standardization for Europe, Lyon, France.
Biologicals ; 67: 94-111, 2020 Sep.
Article in En | MEDLINE | ID: mdl-32660862
ABSTRACT
The IABS-EU, in association with PROVAXS and Ghent University, hosted the "2nd Conference on Next Generation Sequencing (NGS) for Adventitious Virus Detection in Human and Veterinary Biologics" held on November 13th and 14th 2019, in Ghent, Belgium. The meeting brought together international experts from regulatory agencies, the biotherapeutics and biologics industries, contract research organizations, and academia, with the goal to develop a scientific consensus on the readiness of NGS for detecting adventitious viruses, and on the use of this technology to supplement or replace/substitute the currently used assays. Participants discussed the progress on the standardization and validation of the technical and bioinformatics steps in NGS for characterization and safety evaluation of biologics, including human and animal vaccines. It was concluded that NGS can be used for the detection of a broad range of viruses, including novel viruses, and therefore can complement, supplement or even replace some of the conventional adventitious virus detection assays. Furthermore, the development of reference viral standards, complete and correctly annotated viral databases, and protocols for the validation and follow-up investigations of NGS signals is necessary to enable broader use of NGS. An international collaborative effort, involving regulatory authorities, industry, academia, and other stakeholders is ongoing toward this goal.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Viruses / Biological Products / Vaccines / Drug Contamination / High-Throughput Nucleotide Sequencing Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Viruses / Biological Products / Vaccines / Drug Contamination / High-Throughput Nucleotide Sequencing Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article